Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James

Raymond James upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a moderate buy rating in a report issued on Thursday,Zacks.com reports.

Several other analysts have also commented on the stock. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Up 1.3 %

Dianthus Therapeutics stock opened at $23.81 on Thursday. The company has a fifty day simple moving average of $26.09 and a 200-day simple moving average of $26.57. The firm has a market capitalization of $704.78 million, a price-to-earnings ratio of -9.52 and a beta of 1.74. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. On average, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the company. Quest Partners LLC increased its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. Fred Alger Management LLC grew its position in shares of Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after buying an additional 3,316 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at $112,000. MetLife Investment Management LLC raised its stake in Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after acquiring an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.